{"id":39252,"date":"2026-07-30T10:49:00","date_gmt":"2026-07-30T14:49:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/novartis-pharmaceuticals-corporation-v-cipla-usa-inc\/"},"modified":"2026-06-17T02:15:34","modified_gmt":"2026-06-17T06:15:34","slug":"novartis-pharmaceuticals-corporation-v-cipla-usa-inc","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/novartis-pharmaceuticals-corporation-v-cipla-usa-inc\/","title":{"rendered":"Novartis Pharmaceuticals Corporation v. Cipla USA Inc."},"content":{"rendered":"<p><strong>Litigation Summary and Analysis: Novartis Pharmaceuticals Corporation v. Cipla USA Inc. (D.N.J.) | Case No. 1:26-cv-00272<\/strong><\/p>\n<p><strong>Executive summary.<\/strong> The action is a Hatch-Waxman patent infringement suit in the District of New Jersey brought by Novartis Pharmaceuticals Corporation against Cipla USA Inc. under case number 1:26-cv-00272. The complaint and docket events needed to produce a complete infringement-and-procedure analysis (asserted patents, Orange Book drug details, Paragraph IV theory, requested relief, claim construction posture, and current status) are not present in the provided material, so no accurate, citation-backed litigation summary can be generated.<\/p>\n<h2><strong>What patents are asserted in Novartis v. Cipla USA Inc. 1:26-cv-00272?<\/strong><\/h2>\n<p><strong>Featured-snippet answer.<\/strong> Not determinable from the provided information.  <\/p>\n<h3><strong>Which patent numbers and claims does Novartis assert?<\/strong><\/h3>\n<p>Not determinable. A litigation analysis requires the asserted patent list from the complaint (typically the \u201cList of Patents\u201d section and the infringement counts referencing specific claims).<\/p>\n<h3><strong>Are patents for the active ingredient, formulation, or method-of-use asserted?<\/strong><\/h3>\n<p>Not determinable. Hatch-Waxman complaints typically split asserted patents into drug substance, formulation, and\/or method-of-use. That breakdown cannot be derived from the case caption\u2026<\/p>","protected":false},"excerpt":{"rendered":"<p>Litigation Summary and Analysis: Novartis Pharmaceuticals Corporation v. Cipla USA Inc. (D.N.J.) | Case No. 1:26-cv-00272 Executive summary. The action [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":34556,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39252","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39252"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39252\/revisions"}],"predecessor-version":[{"id":39382,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39252\/revisions\/39382"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/34556"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}